Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease

BACKGROUND AND AIMS: Early prediction of the effect of vedolizumab (VDZ) in inflammatory bowel disease (IBD) is of paramount importance to guide clinical decisions. This study assessed whether early fecal calprotectin (FC) can predict endoscopic response and histologic remission after VDZ initiation...

Descripción completa

Detalles Bibliográficos
Autores principales: Pauwels, Renske W. M., van der Woude, Christien J., Erler, Nicole S., de Vries, Annemarie C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768861/
https://www.ncbi.nlm.nih.gov/pubmed/33488771
http://dx.doi.org/10.1177/1756284820979765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768861/
https://www.ncbi.nlm.nih.gov/pubmed/33488771
http://dx.doi.org/10.1177/1756284820979765

Ejemplares similares